Emergence Life Science

Emergence Therapeutics is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for the treatment of high-unmet-need cancers. The company's lead program, ETX-22, is a potential best-in-class ADC targeting Nectin-4, a protein highly expressed in various solid tumors including bladder, breast, and lung cancers. Emergence's technology focuses on optimizing the therapeutic window of ADCs through innovative linker-payload combinations and site-specific conjugation. In June 2023, the company was acquired by Eli Lilly and Company, highlighting the significant potential of its ADC pipeline and expertise. The acquisition aims to accelerate the clinical development of ETX-22 and expand Lilly's oncology portfolio.